SKS. I. Krivenko

S. I. Krivenko

*This is an algorithmically generated author record based on publicly available information.

S. I. Krivenko has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fucoxanthin as a Geroprotector: Experimental Data on Mice

    by A. I. Kapralov, I. Yu. Maklakova, D. Yu. Grebnev, V. V. Bazarnyj, S. I. Krivenko

    Introduction . Th e search for compounds capable of modulating key mechanisms of aging remains one of the pressing challenges of modern medicine. Fucoxanthin, a carotenoid derived from brown algae, possesses antioxidant and anti-infl ammatory properties; however, its eff ects on complex biomarkers of aging in mammals remain insuffi ciently studied. Objective is to comprehensively evaluate the eff ects of long-term oral administration of fucoxanthin on biomarkers of aging, including pro-infl ammatory cytokines, advanced glycation end products, and metabolic parameters in aging mice. Materials and methods . Th e study included 30 male ICR/CD1 mice divided into three groups: 1) mature controls (10 months), 2) aged controls (18 months), and 3) aged mice receiving fucoxanthin (18 months) at a dose of 20 mg/kg body weight per day for 8 months. Serum levels of IL-6, TNF-α, MCP-1, and AGEs, as well as biochemical parameters, were assessed. Results . In aged control mice, all measured markers were signifi cantly higher than in mature controls. Fucoxanthin administration contributed to a reduction in IL-6, TNF-α, MCP-1, and AGEs levels, along with an improvement in the metabolic profi le (decreased glucose, triglycerides, ALT and AST activities, and increased HDL cholesterol and albumin). Conclusion . Th e obtained results demonstrate a comprehensive geroprotective eff ect of fucoxanthin, refl ected in suppression of the senescence-associated secretory phenotype, reduction of carbonyl stress, and improvement of metabolic status. Th ese fi ndings support the potential of fucoxanthin as a promising geroprotector for further research in the prevention of age-associated diseases.

  • Open Access

    Mesenchymal stem cells in liver transplantation: аssessment of long-term results

    by S. V. Korotkov, E. A. Nazarova, E. G. Yurkina, В. В. Смольникова, V. Yu. Grinevich, E. A. Yanushevskaya, A. Yu. Startseva, A. E. Shcherba, S. I. Krivenko, O. O. Rummo, et al.

    Introduction. Transplantation is an effective method of treating patients with end stage liver diseases. Long-term results are determined by two main factors: the development of immunological complications and calcineurin inhibitor nephrotoxity. Application of mesenchymal stem cells (MSCs), which modulate the immune response, is a promising effective method to optimize the treatment results in patients after liver transplantation.The objective of the study was to evaluate the long-term results of mesenchymal stem cells application in liver transplantation.Material and methods. A retrospective study was performed, which included 186 patients after liver transplantation (2015–2023). The MSC group (n=93) received MSCs according to four protocols: local, systemic, combined administration, therapy for acute kidney injury; the control group (n=93) received the standard treatment. The median follow-up was 3 (2;5) years, the follow-up period being from 1-8 years. The patient survival, graft and renal function, depth of immunosuppressive therapy, anti-HLA antibody levels, and lymphocyte immunophenotype were assessed.Results. In the MSC group the incidence of immunological dysfunction of the liver allograft was decreased (22% versus 40%, pConclusion. Using MSCs in liver transplantation improves long-term outcomes by reducing the incidence of immunological complications, preserves the renal function, and reduces the need for high-dose immunosuppression.

  • Open Access

    Intraportal induction of mesenchymal stem cells for immunosuppression induction in liver transplantation

    by S. V. Korotkov, E. A. Primakova, A. A. Symanovich, О. А. Лебедь, T. V. Lebedeva, A. E. Shcherba, S. I. Krivenko, O. O. Rummo

    Background. Despite the effectiveness of modern immunosuppressive therapy protocols, acute rejection remains a significant challenge in liver transplantation (LT), occurring in up to 40% of cases. One promising strategy to improve graft tolerance and reduce rejection rates is the use of mesenchymal stem cells (MSCs). Administering MSCs directly into the regional circulation of the transplanted liver offers the potential to enhance the effects of standard immunosuppressive therapy by exerting a localized immunosuppressive effect at the graft site. Objective: to evaluate the clinical efficacy of intraportal administration of MSCs during the induction phase of immunosuppressive therapy in patients undergoing LT. Materials and methods. A randomized prospective study was conducted involving two groups of LT recipients. In the experimental group (n = 14), patients received an intraportal infusion of MSCs during transplantation at a dose of 20 × 106 cells. The control group (n = 14) underwent standard transplant reperfusion without MSC administration. The study assessed the safety of the MSC infusion procedure, graft function, incidence and severity of acute rejection, renal function, and tacrolimus levels. Additional assessments included histological and immunohistochemical analyses, as well as fluorescence in situ hybridization (FISH). Results. No complications associated with MSC administration were observed. The MSC group demonstrated faster restoration of graft function, with significantly lower levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) by postoperative day 4 (p < 0.05), and normalization of AST achieved by day 10. The incidence of acute rejection was lower in the MSC group (21%) compared to the control group (28%), with only mild to moderate rejection observed in the MSC group. Additionally, expression of matrix metalloproteinase-10 (MMP10) was significantly reduced in the MSC group (p = 0.01). Tacrolimus levels were lower in the MSC group, yet adequate immunosuppression was maintained. This correlated with faster renal function recovery, with serum creatinine levels on day 4 significantly lower in the MSC group compared to controls (80 vs 101 μmol/L, p < 0.05). FISH analysis confirmed the presence of MSCs within the liver graft tissue on postoperative day 7. Conclusion. Intraportal administration of MSCs during LT is a safe approach that enhances faster graft function recovery, reduces the severity of acute rejection, and mitigates tacrolimus-associated nephrotoxicity. These findings support the potential of MSC therapy as a valuable adjunct to standard immunosuppressive regimens in LT.

  • Open Access

    Comparative analysis of the profile of expression of molecular markers of mesenchymal stem cells obtained from placental-umbilical cord complex tissues, adipose tissue and bone marrow

    by E. G. Yurkina, S. I. Krivenko, В. В. Смольникова, E. A. Primakova, E. A. Nazarova, A. A. Symanovich, N. I. Dedyulya, I. A. Romanova, D. Yu. Efimov, A. E. Shcherba, et al.

    Mesenchymal stem cells (MSCs) are multifunctional adult stem cells that can be derived from various tissues, such as adult adipose tissue, peripheral blood, bone marrow, neonatal placenta, and umbilical cord tissue. MSCs have the capacity for self-renewal and multidirectional differentiation. Despite the absence of differences in the expression of the main surface markers, MSCs obtained from tissues of the placenta-umbilical cord complex, adipose tissue and bone marrow differ significantly in their molecular profile. Cellular heterogeneity is ubiquitous across MSC cultures from different species and tissues. During the course of the study, the expression level of cell surface markers that characterize the heterogeneity of MSCs obtained from various sources was assessed. MSCs from all tissues express typical MSC markers on their surface, including CD13, CD73, CD105 and CD90, in the absence of expression of hematopoietic markers (CD14, CD34 and CD45), costimulatory molecules CD86, membrane protein CD154, adhesion molecules CD15, and markers of embryonic stem cells (TRA-1-81 and TRA-1-60R). However, they differed in the expression of stemness markers (October 4, Nanog), coinhibitory molecules (CD273, CD274, and CD200), cell adhesion molecules CD146, surface antigen SSEA-4, and transcription factor GATA4. The results on the molecular profile of MSCs as a heterogeneous cell population allow for the scientific substantiation of the choice of tissue source for the creation of biomedical cell products with specified therapeutic properties.

  • Open Access

    Functional characteristics of lymphocytes and plasma cytokine profile of allogeneic hematopoietic stem cell recipients as risk factors for the development of acute graft-versus-host disease

    by E. A. Prymakova, S. I. Krivenko, A. A. Symanovich, E. G. Yurkina, E. A. Nazarova, E. A. Yanushevskaya, I. N. Dedyulya, I. A. Romanova, H. Y. Startsava, N. F. Milanovich, et al.

    It has been shown that in order to identify patients with high risk for developing immunological complications after allogeneic hematopoietic stem cell transplantation (alloHSCT), it is advisable to measure quantitatively the proliferative activity of lymphocytes in alloHSCT recipients on the day of transplantation. A high donor and recipient lymphocyte stimulation index (>11.55) is an unfavorable factor in terms of development of a graft-versus-host disease (GVHD) in the early posttransplant period. In the course of the work, it was found that the study of the cytokine profile of blood plasma of alloHSC recipients in the early posttransplant period can be used as an additional method for diagnosing GVHD. The levels of IL-8 and IL-21 in the blood plasma of alloHSC recipients can act as potential biomarkers of acute GVHD.

  • Open Access

    Usage of mesenchymal cells from the human placental-umbilical complex in the correction of liver failure in patients with decompensated liver cirrhosis

    by E. G. Yurkina, D. Yu. Efimov, S. I. Krivenko, E. A. Primakova, E. A. Nazarova, A. A. Symanovich, N. I. Dedyulya, В. В. Смольникова, E. A. Yanushevskaya, I. A. Romanova, et al.

    Acute-on-chronic liver failure is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short-term mortality. The treatment is based on the management of complications and, in severe cases, liver transplantation. Liver transplantation is the most effective treatment, but the lack of donor livers and a high cost of transplantation limit its broad application. Human placenta-umbilical cord complex derived mesenchymal stem cells (MSCs) can be considered as an allogeneic source for liver disease. The aim of the study was to assess the safety and potential effectiveness of systemic administration of mesenchymal cells from the human placental-umbilical cord complex for liver failure correction in patients with decompensated cirrhosis of the liver. An open interventional prospective case-control study was conducted, including 40 patients over 18 years of age with decompensated liver cirrhosis who were hospitalized awaiting liver transplantation. Laboratory efficacy of therapy was confirmed by a significant decrease in a total bilirubin level by 39 %, an increase in total protein was noted (by 11 %), as well as stabilization of coagulopathy (decrease in INR by 25 %). Systemic administration of mesenchymal cells of placental origin is a promising therapeutic option for patients with decompensated liver cirrhosis, allowing one to increase the waiting period for emergency liver transplantation and stabilize the clinical course of the disease.

  • Open Access

    Use of autologous platelet-rich plasma in knee osteoarthritis symptomatic treatment

    by D. V. Bukach, O. L. Eismont, M. P. Potapnev, V. I. Asaevich, P. V. Litskevich, F. N. Karpenko, S. I. Krivenko, V. G. Bogdan, V. V. Vusau, К. Е. Хахелько

    Among the conservative methods of treatment of osteoarthritis the use of plasma enriched with soluble platelet factors /platelet-rich plasma (PORFT/PRP) is becoming increasingly attractive.The aim of the study was to determine the tolerability and effect of intra-articular administration of standardized autologous PRP on patients with knee osteoarthritis status based on the survey results. Patients with knee osteoarthritis (OA) received standard drug therapy (n = 19) or additionally standardized autologous platelet-rich plasma (PRP) (n = 21). Intraarticular injection of 6 ml of PRP was carried out three times every two weeks. The administration safety was assessed. Patients were questioned with an assessment of VAS and WOMAC scales in 2 weeks, 1 month and 3 months after starting the treatment. It was shown that three-time intra-articular administration of standardized autologous PRP was safe for a patient. At the same time, the pain syndrome decreased (VAS score) and the knee joint function improved (WOMAC score) after 1 and 3 months. All indicators were significantly better compared to the control group. We concluded that standardized autologous PORFT with three intra-articular injections is safe and has an analgesic effect and preserves the function of the knee joint already within 1–3 months of observation.


  • Open Access

    The use of mesenchymal stem cells in the treatment of severe forms of new coronavirus infection COVID-19: a prospective observational study

    by Aleksandr M. Dzyadzko, S. I. Krivenko, A. V. Syradouey, N. I. Dedylya, P. S. Prylutski, E. A. Prymakova, A. A. Symanovich, E. A. Nazarova, K. H. Petrovskaya, V. V. Smolnikova, et al.

    INTRODUCTION: One of the promising treatments for COVID-19 aimed at correcting the immune response and reducing the level of pro-inflammatory cytokines is the use of mesenchymal stem cells (MSCs). There is evidence that MSCs, due to various mechanisms, are able to suppress the cytokine storm in patients with COVID-19. Thus, the use of MSCs can contribute to the suppression of inflammation and the regulation of immune homeostasis in patients with severe COVID-19. OBJECTIVE: Evaluation of the effect of mesenchymal stem cell (MSC) therapy on the course of severe forms of novel coronavirus infection, accompanied by “cytokine storm”. MATERIALS AND METHODS: A prospective single-center study included 39 patients treated for coronavirus infection on the basis of the intensive care unit and, after randomization, randomly divided into control (n = 16) and study groups (n = 23). An assessment of clinical, laboratory parameters in both groups and a cytokine profile in the study group was carried out. Outcomes were compared, the incidence of complications and clinical and laboratory parameters in both groups, and the cytokine profile in the study group. RESULTS: The use of MSCs in patients with severe forms of COVID-19 affected the outcomes of the disease, the duration of stay on mechanical ventilation, the course of acute respiratory distress syndrome (ARDS) (an increase in the oxygenation index in patients of the study group by 5, 7 days from administration in comparison with the control group). CONCLUSIONS: In patients treated with MSCs, there was a significant decrease in a number of pro-inflammatory cytokines.

  • DYNAMICS OF IMMUNOLOGICAL PARAMETERS IN PATIENTS WITH MULTIPLE SCLEROSIS AFTER TRANSPLANTATION OF ALLOGENEIC MESENCHYMAL STEM CELLS

    by Fedulov A. S., Belarusian State Medical University, Zafranskaya M. M., Borisov A. V., Nizhegorodova D. B., Volkova N. A., S. I. Krivenko, Adamovich A. Yu., Primakova E. A., Symanovich A. A., et al.

  • Open Access

    MESENCHYMAL STEM CELLS IN THE COMPLEX TREATMENT OF TRAUMATIC BRAIN INJURY

    by Y.G. Shanko, S.I. Krivenko, V.V. Goncharov, V.V. Novitskaya, A.S. Zamaro, A.L. Tanin, M.A. Nekhai, Y.P. Tokalchik, L.A. Novikova, Z.V. Kolyadich, et al.

    Relevance. The problem of effective prevention and treatment of traumatic brain injuries (TBI) of various etiologies has not been resolved in all countries of the world. Primary brain damage from trauma initiates secondary damage to the nervous tissue. As a result, the interaction of brain neural networks is disrupted and the control of somatic and visceral functions of the body is weakened. The article is based on our own clinical observations and comparison of results with literature data and provides a discussion of the prospects for the use of cell technologies in the prevention of fatal disorders of vital functions control in traumatic brain injuries. Objective. To evaluate the effectiveness of intranasal perineural implantation of mesenchymal stem cells (MSCs) in the complex therapy of patients with TBI. Materials and methods. The technique intranasal perineural administration of MSCs was used in complex therapy of 15 patients with severe TBI. The patients were 19÷69 years old, 13 men and two women. A cell suspension was isolated from the adipose tissue of the patient's abdominal wall and centrifuged for 10 min at 1500 rpm. The cell pellet was washed in phosphate buffered saline and DMEM. Cells were cultured in plastic culture flasks in a humidified atmosphere with 5% CO2 content. The cell mass was trypsinized according to standard technique and resuspended in physiological saline on the day of implantation. Dynamics of culture growth, pluripotency, phenotyping of MSCs were monitored. MSCs were injected under general anesthesia into the submucosa of the nasal cavity 3-4 times with an interval of 3-7 days, depending on the growth rate of MSCs, in a single dose from 12.0×106 to 35.0×106 cells. Results. The use of allogeneic and predominantly autologous MSCs of adipose tissue in the complex treatment of patients with severe TBI by intranasal perineural delivery to the area of traumatic brain injury does not cause complications and is a safe technique. 8 patients with severe TBI showed from 4 to 7 points according to the Glasgow Outcome Scale Extended, with an average of 5.4±1.1 points after 6 months. The main result is that complex therapy, including intranasal implantation of MSCs in acute and subacute periods of severe TBI, contributes to the survival of patients and restoration of neurological – including cognitive – functions control. Conclusions. The effectiveness of intranasal perineural implantation of MSCs in the complex therapy of patients with TBI has been demonstrated. The mechanisms of the beneficial effects of perineural implantation of MSCs in patients with TBI require further research.